Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 10/20 | 0.75 |
| ▸ | RAB9A | P51151 | 9/20 | 0.75 |
| ▸ | MAPT | P10636 | 9/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.75 |
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | MITF | O75030 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061754 | 1.00 | ALOX5 (0.77) | ALOX5NPC1RAB9AMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL9423776 | 0.99 | ALOX5 (0.75) | ALOX5NPC1RAB9AMAPTKMT2A | |
| SCHEMBL5501099 | 0.93 | ALOX5 (0.68) | ALOX5NPC1RAB9AMAPTKMT2A | |
| SCHEMBL23898948 | 0.87 | KMT2A (0.83) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL8572381 | 0.87 | KMT2A (0.83) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL9134339 | 0.87 | KMT2A (0.83) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL4248472 | 0.87 | KMT2A (0.70) | ALOX5NPC1RAB9AMAPTKMT2A | |
| SCHEMBL16587382 | 0.87 | MAPT (0.75) | ALOX5MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8274340 | 0.87 | KMT2A (0.81) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL7872779 | 0.87 | KMT2A (0.81) | NPC1RAB9AMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278965-A1 | NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-07 | — | — | US | disclosed |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4168441-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169916-A1 | CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
| CN-115955968-A | Carbohydrazone acyldinitrile compounds comprising at least two aryl or heteroaryl groups connected by a novel linker and uses thereof | 韩国科学技术研究院 | 2023-04-11 | — | — | CN | disclosed |
| WO-2021257650-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021256902-A1 | CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF | 한국과학기술연구원 | 2021-12-23 | — | — | WO | disclosed |
| CN-108084096-A | 2- phenyl pyrimidine classes compound, preparation method and medical usage | 中国药科大学 | 2018-05-29 | — | — | CN | disclosed |
| US-9833458-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-05 | — | — | US | disclosed |
| US-9808541-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—Of the Commonwealth System of Higher Eduation (US) | 2017-11-07 | — | — | US | disclosed |
| EP-0757670-B1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-01-13 | — | — | EP | disclosed |
| US-5728835-A | HYPOTENSIVE AGENTS; ANTIISCHEMIC AGENTS | TOA EIYO, LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0757670-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995029152-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-02 | — | — | WO | disclosed |
| EP-0661266-A1 | Substituted cyclic amine compounds as 5HT2 antagonists | TOA EIYO LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | disclosed |
| US-5278180-A | 4,5-bis(aryl) 4H-1,2,4-triazoles derivatives and analgesic use | ROUSSEL UCLAF (FR) | 1994-01-11 | — | — | US | disclosed |
| EP-0176444-B1 | PROCESS FOR THE PREPARATION OF DERIVATIVES OF 4H-1,2,4-TRIAZOLE, TRIAZOLES SO OBTAINED, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1989-02-22 | — | — | EP | disclosed |
| EP-0176444-A1 | Process for the preparation of derivatives of 4H-1,2,4-triazole, triazoles so obtained, their use as medicaments, and pharmaceutical compositons containing them | ROUSSEL-UCLAF (FR) | 1986-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278965-A1 | NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | AADAC, CBR3, MTCL3 | ALOX5 4073/4885NPC1 2328/4885RAB9A 1162/4885 |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | ALOX5 4768/4885NPC1 1139/4885RAB9A 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.